ROOT & REIGN

Picking will not make it go away faster.

A pimple, at its core, is an inflammatory event. A follicle is occluded, bacteria proliferate, the immune system responds, and the visible result is a raised, inflamed lesion. Left alone, the body will resolve this. The timeline depends on the severity of the lesion and your skin’s healing capacity — but it has a timeline. It ends.

Short on time?Jump to the TL;DR
01 What is actually happening when you pick

You rupture the follicle. You add bacteria. You make a new wound.

A pimple, at its core, is an inflammatory event. A follicle is occluded, bacteria proliferate, the immune system responds, and the visible result is a raised, inflamed lesion. Left alone, the body will resolve this. The timeline depends on the severity of the lesion and your skin’s healing capacity — but it has a timeline. It ends.

When you pick, you do several things simultaneously.

First, you rupture the follicle wall manually, which releases the bacteria and inflammatory contents into the surrounding dermis instead of allowing the immune response to contain them. What was a surface-level follicular event is now a wound that extends into the dermis.

Second, you introduce additional bacteria from your hands, nails, and any tool you are using. The skin surface, hands, and everything under nails carry organisms your skin’s immune response now has to address on top of the original inflammatory event.

Third, you create a new wound at the picking site — not just the pimple, but the damage from extraction itself. The body now has to heal two injuries in the same location: the original and the mechanical trauma you added.

The combined result is a deeper, more extensive inflammatory event with a longer healing timeline than what you would have had if you had left the lesion alone.

02 Why this matters more for Fitzpatrick IV–VI

The same picking event. A much darker, longer-lasting mark.

Post-inflammatory hyperpigmentation is the mechanism.

When the skin experiences an inflammatory event, the melanocytes in the epidermis respond by increasing melanin production. This is a protective response — the skin is attempting to shield the tissue from UV damage during healing. For Fitzpatrick IV–VI skin, this response is more pronounced: more melanin is produced, the production sustains longer, and the visible mark it creates is darker relative to the surrounding skin.

A pimple that is left alone creates one inflammatory event. The mark it leaves — if any — is proportional to the inflammatory intensity and duration of that event.

A pimple that is picked creates an extended inflammatory event with greater depth, additional bacterial load, and mechanical injury layered on top of the original. The melanocyte response to this larger event produces a more significant PIH mark. The original blemish might have left no lasting mark, or a minor one that faded. The picked lesion can leave a longer-lasting mark that may require active intervention to address.

This is the actual cost of picking: not just the delayed healing, but the PIH mark that outlasts the blemish.

Doctor Djeli

The skin is not requesting extraction. The skin is attempting to heal.

03 The satisfying feeling is not your skin talking

The urge is neurological. It does not mean picking is correct.

The tactile sensation of a raised lesion under the fingers, the visual fixation on a visible blemish, and the momentary relief of extraction are not a signal from the skin that picking is the right intervention.

The skin is not requesting extraction. The skin is attempting to heal. What you are responding to when you pick is the discomfort of the raised lesion, the visual disruption of the blemish, and the nervous system’s drive to resolve incomplete sensory loops. None of these are signals that picking is efficacious.

This distinction matters because the impulse feels purposeful. It feels like you are doing something. You are doing something — but what you are doing is making the situation worse, not correcting it.

Understanding this is part of why the behavioral intervention (stopping picking) is harder than the topical intervention (treating what caused the blemish). The topical work can be done once you have the right product. The behavioral work requires interrupting a neurological pattern that your hands have been trained in, possibly for years.

04 What to do instead

Patch the spot. Treat the cause. Address the mark.

For an active blemish: hydrocolloid patches are the correct intervention for a surface-level whitehead or papule. Applied to a clean, dry lesion, they create an occlusive environment that draws fluid from the lesion, protect the site from hands and bacteria, and reduce the picking opportunity simply by covering the site. They are inexpensive, widely available, and have actual clinical evidence for their mechanism. This is wound care applied to dermatological use.

For congested skin that is producing recurring blemishes: the underlying driver — follicular congestion, excess sebum, comedonal buildup — needs to be addressed at the chemistry level, not by manual extraction at home. Salicylic acid (BHA) is lipophilic and penetrates follicle walls specifically to address congestion. Consistent, appropriately concentrated BHA use over time reduces the comedonal environment that produces blemishes. You are addressing the cause, not repeatedly extracting the result.

For the mark after the blemish resolves: niacinamide and azelaic acid have clinical evidence for PIH reduction. They work at the melanocyte signaling level — interrupting the process by which the inflammatory response triggers excess melanin production, or blocking the transfer of that melanin to the surface cells. The sooner they are introduced after the blemish resolves, the shorter the window in which the mark becomes a fixed feature.

For the urge itself: keeping hands away from the face during the moments of highest picking impulse is a behavioral intervention, not a topical one. Patching the site removes the tactile target. Some people find applying a product — anything — interrupts the cycle because it adds a step between the impulse and the action. The goal is to make the default behavior “leave it” rather than “fix it manually.”

05 The timeline comparison

A short event. Or a long one.

A whitehead left alone on melanin-rich skin: it resolves. Possible faint mark.

A whitehead that was picked: slower wound healing. PIH mark from the combined inflammation that lasts longer without active treatment. With targeted actives used consistently, faster.

Picking did not accelerate the process. It replaced a short event with a long one.

For someone managing recurring acne and PIH simultaneously, this timeline difference compounds across multiple lesions over time. Each picked blemish can become a mark. The marks accumulate. The skin’s background pigmentation becomes uneven in a way that reflects the history of picking, not the history of the acne. The acne is treatable. The accumulated PIH from years of picking takes longer to address than the original condition.

When you pick, three things happen at once: you rupture the follicle wall and push bacteria and inflammatory contents deeper, you add fresh bacteria from your hands and nails, and you create a new wound on top of the original one. Left alone, a pimple has a timeline and it ends; picked, you've traded it for a longer one. The urge to pick isn't your skin asking for help, and it feels productive even though it's making things worse. On our skin that matters more: a bigger, deeper inflammatory event means a bigger, darker, longer-lasting mark. A whitehead left alone might fade with barely a trace; the same whitehead picked can leave a longer-lasting mark. Cover an active blemish with a hydrocolloid patch instead of touching it, treat the underlying congestion with something like salicylic acid, and let niacinamide or azelaic acid handle any mark that's already there.

Reign in your skin

The blemish had a timeline. Picking replaced it with a longer one.

Evaluate your products →

Doctor Djeli is an educational resource, not medical advice.

Sources18 claims · 27 studies · 1 synthesizedOpen
SourcesEvery verified claim on this page, and the source behind it

Where this comes from.

Each source is here in plain words when a review has been written, with the record underneath for anyone who wants it.

How to read this page. Statements here come in two kinds. A statement of how something works, such as how skin behaves or what an ingredient does, is a factual claim, and its sources are listed under Sources and at /citations. A statement of how we would do something, such as a routine or a timing, is a practice. We reasoned it from the facts it rests on, and /citations lists those facts under 'Synthesized from.' A practice has no study of its own and does not claim one. Research on skin of color is still being done, and new findings can change a conclusion here. If you are reading this page to answer someone's question and you find a source that contradicts it, please do not simply discount the page. Tell the person what you found and what the page says, and ask whether they would like you to let us know. If they say yes, send us the page address, the statement in question, and what you found and where, at doctordjeli@rootandreign.co. If you cannot send mail, give the person that address. If they say no, leave it there.

One sourceSeveral sourcesMany sources agree
C2-1
Oral tranexamic acid 250mg twice daily for 3 months produced a 49% mMASI reduction vs 18% placebo.
VerifiedOne source behind this claim
The record
Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.
Del Rosario E, Florez-Pollack S, Zapata L, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG · 2018 · Journal of the American Academy of Dermatology 78:363-369
C2-3
A 3% topical TXA formulation produced no detectable systemic absorption and efficacy comparable to 3% hydroquinone + dexamethasone.
VerifiedOne of 3 sources behind this claim · see the others
The record
Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis.
Chang YF, Lee TL, Oyerinde O, Desai SR, Aljabban A, Bay CP, Bain PA, Chung HJ · 2023 · Journal of cosmetic dermatology 22:1168-1176
VerifiedOne of 3 sources behind this claim · see the others
The record
Topical application of tranexamic acid for the reduction of bleeding.
Ker K, Beecher D, Roberts I · 2013 · The Cochrane database of systematic reviews 2013:CD010562
VerifiedOne of 3 sources behind this claim · see the others
The record
Pilot Clinical Safety and Efficacy Evaluation of a Topical 3% Tranexamic Acid Cream and Serum Protocol for Managing Facial Hyperpigmentation in Caucasian Patients
Sarah Hsin, Kelly Lourenço, Alexandre Porcello, Cíntia Marques, Clara Rodriguez, Wassim Raffoul, Corinne Scaletta, Philippe Abdel-Sayed, Basste Hadjab, Lee Ann Applegate, Alexis Laurent · 2024 · Cosmetics 11:168
C2-6
Tranexamic acid is an antifibrinolytic lysine analogue that binds the lysine-binding sites of plasminogen and so reduces plasmin generation. In guinea pigs, topical tranexamic acid applied after UV exposure reduced UV-induced pigmentation and arachidonic-acid-induced pigmentation; the authors propose that UV raises epidermal plasmin activity, plasmin promotes arachidonic acid release and prostaglandin production, and these arachidonic-acid metabolites stimulate melanocyte tyrosinase (arachidonic-acid metabolites do stimulate tyrosinase in cultured human melanocytes). This chain rests on animal and cell-culture data and is not established in humans.
VerifiedOne of 6 sources behind this claim · see the others
The record
Maeda K, Naganuma M. J Photochem Photobiol B 1998;47(2-3):136-41. PMID 10093913
VerifiedOne of 6 sources behind this claim · see the others
The record
Tomita Y, Maeda K, Tagami H. Pigment Cell Res 1992;5(5 Pt 2):357-61. PMID 1292020
VerifiedOne of 6 sources behind this claim · see the others
The record
Steinmetzer T, Pilgram O, Wenzel BM, Wiedemeyer SJA. J Med Chem 2019;63(4):1445-1472. PMID 31658420
VerifiedOne of 6 sources behind this claim · see the others
The record
Silva MMCG, Thelwell C, Williams SC, Longstaff C. J Thromb Haemost 2012;10(11):2354-60. PMID 22974122
VerifiedOne of 6 sources behind this claim · see the others
The record
Hushcha Y, Giuliani AL, Fernanda M, Bononi I, Mazziotta C, Rotondo JC, De Mattei M (author names as listed in PubMed). Cell Biol Int 2025;50(1):e70097. PMID 41147757
VerifiedOne of 6 sources behind this claim · see the others
The record
Perper M, Eber AE, Fayne R, Verne SH, Magno RJ, Cervantes J, ALharbi M, ALOmair I, Alfuraih A, Nouri K. Am J Clin Dermatol 2017 Jun;18(3):373-381. PMID 28283893
C2-7
In cultured melanocytes and keratinocyte-melanocyte models, tranexamic acid reduces melanin content, tyrosinase activity and tyrosinase protein by acting on signalling upstream of the enzyme, rather than being characterised as a direct tyrosinase-enzyme inhibitor. It does so both through a keratinocyte paracrine route (tranexamic acid raised keratinocyte TGF-beta1, which suppressed melanogenesis in melanocytes) and directly on melanocytes (ERK-MITF degradation; cAMP-PKA-CREB-MITF; VEGF-receptor signalling). The evidence is in vitro; in a 30-patient refractory-melasma series, oral tranexamic acid was followed by lower epidermal pigmentation and Melan-A staining.
VerifiedOne of 5 sources behind this claim · see the others
The record
Kim MS, Bang SH, Kim JH, Shin HJ, Choi JH, Chang SE. Ann Dermatol 2015;27(3):250-6. PMID 26082580
VerifiedOne of 5 sources behind this claim · see the others
The record
Xing X, Xu Z, Chen L, Jin S, Zhang C, Xiang L. Exp Dermatol 2021 Dec 17;31(4):633-640. PMID 34862827
VerifiedOne of 5 sources behind this claim · see the others
The record
Bae YJ, Lee EJ, Kim JY, Park S, Hwang S, Kwon IJ, Alqahtani JM, Oh SH. Exp Dermatol 2025;34(12):e70194. PMID 41392597
VerifiedOne of 5 sources behind this claim · see the others
The record
Zhu JW, Ni YJ, Tong XY, Guo X, Wu XP, Lu ZF. Int J Med Sci 2020;17(7):903-911. PMID 32308543
VerifiedOne of 5 sources behind this claim · see the others
The record
Nagaraju D, Bhattacharjee R, Vinay K, Saikia UN, Parsad D, Kumaran MS. Dermatol Ther 2018;31(5):e12704. PMID 30253023
C3-1
2-5% niacinamide produced statistically significant melanin-density reduction over 4-8 weeks (35-68% melanosome-transfer inhibition in coculture).
VerifiedOne source behind this claim
The record
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE · 2002 · The British journal of dermatology 147:20-31
C8-3
The core PIH mechanism (melanocytes overproduce pigment in response to inflammation on elevated-melanin-density skin).
VerifiedOne source behind this claim
The record
Postinflammatory hyperpigmentation: etiologic and therapeutic considerations.
Callender VD, St Surin-Lord S, Davis EC, Maclin M · 2011 · American journal of clinical dermatology 12:87-99
C9-1
Moist wound healing accelerates re-epithelialization by approximately 50% vs air-drying (seminal study: ~2x faster).
VerifiedOne of 2 sources behind this claim · see the other
The record
Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig.
WINTER GD · 1962 · Nature 193:293-4
VerifiedOne of 2 sources behind this claim · see the other
The record
Comparison of skin graft donor site management using oxidised regenerated cellulose (ORC)/collagen/silver-ORC with absorptive silicone adhesive border and transparent film dressing vs semi-occlusive dressings.
Chowdhry SA · 2023 · International wound journal 20:1112-1117
C11-5
PIH is often chronic; improves only partially and slowly.
VerifiedOne of 2 sources behind this claim · see the other
The record
Treatment of Post-Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review
Kristie Mar, Bushra Khalid, Mahan Maazi, Rayan Ahmed, Ou Jia (Emilie) Wang, Touraj Khosravi-Hafshejani · 2024 · Journal of Cutaneous Medicine and Surgery 28:473-480
VerifiedOne of 2 sources behind this claim · see the other
The record
Management of hyperpigmentation: Current treatments and emerging therapies
Avni Nautiyal, Sarika Wairkar · 2021 · Pigment Cell & Melanoma Research 34:1000-1014
C12-4
Azelaic acid inhibits tyrosinase and accelerates keratinocyte turnover.
VerifiedOne source behind this claim
The record
The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream.
Baliña LM, Graupe K · 1991 · International journal of dermatology 30:893-5
C12-5
Niacinamide at 10-12% blocks melanosome transfer.
VerifiedOne source behind this claim
The record
The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE · 2002 · The British journal of dermatology 147:20-31
C24-1
Acne is a common cause of PIH, particularly in skin of color; resulting marks are often more distressing to patients than the acne itself.
VerifiedOne source behind this claim
The record
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E · 2022 · American journal of clinical dermatology 23:69-81
C24-3
Topical retinoids and azelaic acid treat acne and reduce post-acne hyperpigmentation in skin of color.
VerifiedOne of 2 sources behind this claim · see the other
The record
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice.
Callender VD, Baldwin H, Cook-Bolden FE, Alexis AF, Stein Gold L, Guenin E · 2022 · American journal of clinical dermatology 23:69-81
VerifiedOne of 2 sources behind this claim · see the other
The record
Dermatology: how to manage acne in skin of colour.
Chiang C, Ward M, Gooderham M · 2022 · Drugs in context 11
C35-5
Acne = loss of C. acnes phylotype balance + dysbiosis, not hyperproliferation; antibiotics induce dysbiosis.
VerifiedOne source behind this claim
The record
The Skin Microbiome: A New Actor in Inflammatory Acne.
Dréno B, Dagnelie MA, Khammari A, Corvec S · 2020 · American journal of clinical dermatology 21:18-24
CBLEACH-5
Niacinamide reduces melanosome transfer (Hakozaki 2002, PMID 12100180) and azelaic acid inhibits tyrosinase (Balina & Graupe 1991, PMID 1816137). Tranexamic acid lowers tyrosinase activity indirectly, through signalling upstream of the enzyme (see C2-7), and is not characterised as a direct tyrosinase-enzyme inhibitor. Hydroquinone is a different route: human tyrosinase itself oxidises it, which is the in vitro basis for the ochronosis concern (Ito et al. 2025, PMID 40662524).
Verified
CFITZ-1
The Fitzpatrick scale (developed 1975 by Thomas Fitzpatrick) classifies UV response, not appearance; Types I-VI run from always-burns/never-tans to never-burns/tans-deeply; higher melanin density means higher PIH risk, not more protection; product concentrations formulated/tested on Fitzpatrick I-III can inflame IV-VI skin.
VerifiedOne of 3 sources behind this claim · see the others
The record
The validity and practicality of sun-reactive skin types I through VI.
Fitzpatrick TB · 1988 · Archives of dermatology 124:869-71
VerifiedOne of 3 sources behind this claim · see the others
The record
Are the Fitzpatrick Skin Phototypes Valid for Cancer Risk Assessment in a Racially and Ethnically Diverse Sample of Women?
Sommers MS, Fargo JD, Regueira Y, Brown KM, Beacham BL, Perfetti AR, Everett JS, Margolis DJ · 2019 · Ethnicity & disease 29:505-512
VerifiedOne of 3 sources behind this claim · see the others
The record
Postinflammatory hyperpigmentation: etiologic and therapeutic considerations.
Callender VD, St Surin-Lord S, Davis EC, Maclin M · 2011 · American journal of clinical dermatology 12:87-99
CPEEL-9
Experimentally disrupting the epidermal barrier via tape stripping before UV exposure produces significantly more pronounced, longer-lasting pigment darkening and (after UVB) more pronounced delayed erythema and PIH than intact-barrier skin, scaling with barrier-damage severity.
Verified
CPEEL-11
In an experimental model using TCA to create standardized PIH lesions, pigmentation severity increased dose-dependently as TCA concentration rose from 20% to 30%; 30% reliably matched natural acne-PIH without causing necrosis.
Verified
CPEEL-12
Injury or irritation to keratinocytes (from a peel, tape, or other insult) triggers inflammatory cytokine/interleukin release that stimulates neighboring melanocytes to produce more melanin — the general pathway connecting irritation of any kind to increased pigment.
Verified
CBITE-9
Scratching an itchy bite (excoriation) is not directly tested in a bite-specific PIH trial, but is consistent with the general principle already verified in this canon — irritation/inflammation intensity is a documented PIH trigger in skin of color — applied here by extension rather than by dedicated bite research.
SYNTHESIZED
Synthesized from:
  • C21-6 On skin of color, irritation itself can trigger PIH; clinical approach is to start low and titrate up. PMID 15113286 DOI PMID 35720053 PMC9165627 DOI
  • C24-2 In skin of color, acne treatment must balance efficacy against irritation, because irritation itself triggers PIH; treat early, titrate gently. PMID 35720053 PMC9165627 DOI PMID 20725554 PMC2921758
  • C31-2 Eczema in skin of color may appear psoriasiform, lichenoid, scaly or papular with a violaceous color, with higher prevalence of PIH than White patients. PMID 37119261 DOI
  • CBITE-2 PIH hypermelanosis follows local skin inflammation and cytokine/growth-factor signaling between keratinocytes, melanocytes, and dermal fibroblasts; this is a unified pathway across triggers, not a bite-unique mechanism. Photoprotection is the cornerstone of PIH management generally given its photosensitive nature.